Orthogonal analysis of mitochondrial function in Parkinson's disease patients

Sander Barnhoorn,Chiara Milanese,Tracy Li,Lieke Dons,Mehrnaz Ghazvini,Martina Sette,Stefania Farina,Daisy Sproviero,Cesar Payan-Gomez,Pier G. Mastroberardino

DOI: https://doi.org/10.1038/s41419-024-06617-6

2024-04-03

Cell Death and Disease

Abstract:The etiopathology of Parkinson's disease has been associated with mitochondrial defects at genetic, laboratory, epidemiological, and clinical levels. These converging lines of evidence suggest that mitochondrial defects are systemic and causative factors in the pathophysiology of PD, rather than being mere correlates. Understanding mitochondrial biology in PD at a granular level is therefore crucial from both basic science and translational perspectives. In a recent study, we investigated mitochondrial alterations in fibroblasts obtained from PD patients assessing mitochondrial function in relation to clinical measures. Our findings demonstrated that the magnitude of mitochondrial alterations parallels disease severity. In this study, we extend these investigations to blood cells and dopamine neurons derived from induced pluripotent stem cells reprogrammed from PD patients. To overcome the inherent metabolic heterogeneity of blood cells, we focused our analyses on metabolically homogeneous, accessible, and expandable erythroblasts. Our results confirm the presence of mitochondrial anomalies in erythroblasts and induced dopamine neurons. Consistent with our previous findings in fibroblasts, we observed that mitochondrial alterations are reversible, as evidenced by enhanced mitochondrial respiration when PD erythroblasts were cultured in a galactose medium that restricts glycolysis. This observation indicates that suppression of mitochondrial respiration may constitute a protective, adaptive response in PD pathogenesis. Notably, this effect was not observed in induced dopamine neurons, suggesting their distinct bioenergetic behavior. In summary, we provide additional evidence for the involvement of mitochondria in the disease process by demonstrating mitochondrial abnormalities in additional cell types relevant to PD. These findings contribute to our understanding of PD pathophysiology and may have implications for the development of novel biomarkers and therapeutic strategies.

cell biology

What problem does this paper attempt to address?

The problems that this paper attempts to solve mainly focus on the systematic nature and causality of mitochondrial dysfunction in patients with Parkinson's disease (PD). Specifically, the research aims to:

1. **Verify whether mitochondrial dysfunction is prevalent in different cell types in Parkinson's disease**: By analyzing mitochondrial function in erythroblasts and induced dopaminergic neurons (iDANs) derived from induced pluripotent stem cells (iPSCs) of Parkinson's disease patients, researchers hope to confirm whether mitochondrial abnormalities in these cell types are related to the pathophysiological process of Parkinson's disease.

2. **Explore the relationship between mitochondrial dysfunction and disease severity**: Researchers detect the mitochondrial function of erythroblasts and dopaminergic neurons in Parkinson's disease patients with different disease severities, attempting to reveal whether the degree of mitochondrial dysfunction is associated with the clinical manifestations of the disease.

3. **Evaluate the reversibility of mitochondrial dysfunction**: Researchers detect changes in mitochondrial respiratory function under different culture conditions (such as glucose and galactose media) to determine whether mitochondrial dysfunction can be reversed, especially whether mitochondrial respiratory function is enhanced when glycolysis is restricted in galactose media.

4. **Explore differences in mitochondrial function among different cell types**: Researchers compare the mitochondrial function of erythroblasts and dopaminergic neurons under different conditions to understand the differences in bioenergetic behavior between these two cell types.

Through these studies, the paper aims to further clarify the role of mitochondrial dysfunction in the pathogenesis of Parkinson's disease and provide a theoretical basis for the development of new biomarkers and treatment strategies.